<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03583346</url>
  </required_header>
  <id_info>
    <org_study_id>MS200572_0003</org_study_id>
    <secondary_id>2018-000797-29</secondary_id>
    <nct_id>NCT03583346</nct_id>
  </id_info>
  <brief_title>Multiple Ascending Doses (MAD) of Anti-A Disintegrin and Metalloproteinase With Thrombospondin Motifs-5 (Anti-ADAMTS-5) Nanobody in Participants With Knee Osteoarthritis (OA)</brief_title>
  <official_title>A Phase Ib, Single-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multiple Ascending Dose Study to Assess Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Injections of M6495 (Anti-ADAMTS-5 Nanobody) in Participants With Symptomatic Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck KGaA, Darmstadt, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be conducted in participants with symptomatic knee OA to explore the safety,
      tolerability, immunogenicity, pharmacokinetics (PK), and pharmacodynamics (PD) of MAD of
      M6495.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 23, 2018</start_date>
  <completion_date type="Actual">July 31, 2019</completion_date>
  <primary_completion_date type="Actual">July 31, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrences of Treatment-emergent Adverse Events (TEAEs), Treatment-related AEs and Serious AEs (SAEs)</measure>
    <time_frame>Day 1 up to Day 106</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Change From Baseline in Vital Signs, Laboratory Parameters and 12-lead Electrocardiogram (ECG) Findings</measure>
    <time_frame>Day 1 up to Day 106</time_frame>
    <description>Number of participants with clinically significant change from baseline will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrences of Injection Site Reactions</measure>
    <time_frame>Day 1 up to Day 43</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Serum Concentration (Cmax) of M6495</measure>
    <time_frame>Day 1 up to Day 106</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Normalized Maximum Serum Concentration (Cmax/Dose) of M6495</measure>
    <time_frame>Day 1 up to Day 106</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratio for Cmax (Racc [Cmax]) of M6495</measure>
    <time_frame>Day 1, 15 and 29</time_frame>
    <description>Following Racc parameters will be measured:
Racc15 (Cmax): Cmax at Day 15/Cmax at Day 1
Racc29 (Cmax): Cmax at Day 29/Cmax at Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of M6495 as Assessed by Antidrug Antibodies (ADA) Assays</measure>
    <time_frame>Day 1 up to Day 106</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>M6495</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M6495</intervention_name>
    <description>Participants will receive escalated dose of M6495 bi-weekly on Day 1, 15 and 29 in cohort 1 to 3 and weekly on Day 1, 8, 15, 22, 29 and 36 in cohort 4.</description>
    <arm_group_label>M6495</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive placebo matched to M6495 bi-weekly on Day 1, 15 and 29 in cohort 1 to 3 and weekly on Day 1, 8, 15, 22, 29 and 36 in cohort 4.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Kellgren Lawrence (KL) radiological Grade of 2 to 4 in the target knee

          -  Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscore
             of greater than or equal to (&gt;=) 40 out of 100 in the target knee at screening

          -  Primary or post-traumatic femorotibial OA according to American College of
             Rheumatology clinical and radiographic criteria

          -  Have completed at least 4 days of the participant 7-day diary in the period from Day
             -8 to Day 1

          -  Can give signed informed consent

          -  Other protocol defined inclusion criteria could apply

        Exclusion Criteria:

          -  History of arthroscopy or intra-articular administration of corticosteroids or
             hyaluronic acid into the target knee within 6 months before screening

          -  Intention of having major knee surgeries or total knee replacement during the time
             frame of this study in either knee

          -  Secondary OA in target knee joint because of joint dysplasia, aseptic osteonecrosis,
             acromegaly, Paget disease, Stickler syndrome, hemochromatosis, gout,
             chondrocalcinosis, or calcium pyrophosphate deposition disease

          -  Any known active systemic infection, including infection that might compromise the
             immune system such as human immunodeficiency virus, or hepatitis B or C

          -  History of myocardial infarction or cerebrovascular event within 6 months prior to
             screening, or current active angina pectoris, symptomatic heart failure, seizures,
             untreated hypertension, gastrointestinal bleeding, or any other significant medical
             condition in the Investigator's opinion

          -  History of cancer, except adequately treated basal cell or squamous cell carcinoma of
             the skin or carcinoma in situ/cervical intraepithelial neoplasia of the uterine
             cervix, unless considered cured &gt;= 5 years

          -  Other protocol defined exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DanTrials ApS</name>
      <address>
        <city>Copenhagen NV</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 28, 2018</study_first_submitted>
  <study_first_submitted_qc>June 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2018</study_first_posted>
  <last_update_submitted>January 22, 2020</last_update_submitted>
  <last_update_submitted_qc>January 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>M6495</keyword>
  <keyword>Anti-ADAMTS-5 Nanobody</keyword>
  <keyword>Osteoarthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

